Lyka Labs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 26, 2025, 1:31 pm

Market Cap	410 Cr.
Current Price	115
High / Low	177/90.2
Stock P/E	51.7
Book Value	29.0
Dividend Yield	0.00 %
ROCE	9.93 %
ROE	9.24 %
Face Value	10.0
PEG Ratio	1.06

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Lyka Labs Ltd

Competitors of Lyka Labs Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,566.61 Cr	1,158.58		103.22	194.43	0.31%	16.65%	15.19%	6.18

All Competitor Stocks of Lyka Labs Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	35.19	27.49	25.53	17.82	22.24	22.88	27.99	32.56	27.77	30.11	41.16	33.80	33.43
Expenses	22.59	21.18	20.50	15.61	18.94	20.24	23.82	25.69	25.75	26.40	36.21	28.61	29.35
Operating Profit	12.60	6.31	5.03	2.21	3.30	2.64	4.17	6.87	2.02	3.71	4.95	5.19	4.08
OPM %	35.81%	22.95%	19.70%	12.40%	14.84%	11.54%	14.90%	21.10%	7.27%	12.32%	12.03%	15.36%	12.20%
Other Income	-2.27	0.95	0.98	-5.95	0.02	0.38	-0.18	0.54	0.32	0.56	0.03	0.83	0.82
Interest	2.99	2.91	3.03	3.08	2.85	1.35	1.19	1.28	1.07	0.65	0.54	0.61	0.47
Depreciation	9.46	3.59	3.62	3.47	3.47	3.47	3.59	2.84	2.90	1.76	1.76	1.83	1.42
Profit before tax	-2.12	0.76	-0.64	-10.29	-3.00	-1.80	-0.79	3.29	-1.63	1.86	2.68	3.58	3.01
Tax %	607.08%	6.58%	-46.88%	2.24%	0.00%	7.22%	-22.78%	38.60%	28.22%	30.65%	28.36%	24.30%	32.89%
Net Profit	-15.07	0.60	-0.38	-10.42	-3.01	-1.85	-0.49	1.78	-2.09	1.44	2.10	2.70	2.03
EPS in Rs	-5.25	0.21	-0.13	-3.63	-0.98	-0.56	-0.15	0.54	-0.63	0.40	0.59	0.76	0.57

Last Updated: May 31, 2025, 8:34 am

Below is a detailed analysis of the quarterly data for Lyka Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 33.43 Cr.. The value appears to be declining and may need further review. It has decreased from 33.80 Cr. (Dec 2024) to 33.43 Cr., marking a decrease of 0.37 Cr..
For Expenses, as of Mar 2025, the value is 29.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.61 Cr. (Dec 2024) to 29.35 Cr., marking an increase of 0.74 Cr..
For Operating Profit, as of Mar 2025, the value is 4.08 Cr.. The value appears to be declining and may need further review. It has decreased from 5.19 Cr. (Dec 2024) to 4.08 Cr., marking a decrease of 1.11 Cr..
For OPM %, as of Mar 2025, the value is 12.20%. The value appears to be declining and may need further review. It has decreased from 15.36% (Dec 2024) to 12.20%, marking a decrease of 3.16%.
For Other Income, as of Mar 2025, the value is 0.82 Cr.. The value appears to be declining and may need further review. It has decreased from 0.83 Cr. (Dec 2024) to 0.82 Cr., marking a decrease of 0.01 Cr..
For Interest, as of Mar 2025, the value is 0.47 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.61 Cr. (Dec 2024) to 0.47 Cr., marking a decrease of 0.14 Cr..
For Depreciation, as of Mar 2025, the value is 1.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.83 Cr. (Dec 2024) to 1.42 Cr., marking a decrease of 0.41 Cr..
For Profit before tax, as of Mar 2025, the value is 3.01 Cr.. The value appears to be declining and may need further review. It has decreased from 3.58 Cr. (Dec 2024) to 3.01 Cr., marking a decrease of 0.57 Cr..
For Tax %, as of Mar 2025, the value is 32.89%. The value appears to be increasing, which may not be favorable. It has increased from 24.30% (Dec 2024) to 32.89%, marking an increase of 8.59%.
For Net Profit, as of Mar 2025, the value is 2.03 Cr.. The value appears to be declining and may need further review. It has decreased from 2.70 Cr. (Dec 2024) to 2.03 Cr., marking a decrease of 0.67 Cr..
For EPS in Rs, as of Mar 2025, the value is 0.57. The value appears to be declining and may need further review. It has decreased from 0.76 (Dec 2024) to 0.57, marking a decrease of 0.19.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:54 pm

Metric	Jun 2014n n 15m	Jun 2015	Mar 2016n n 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	119	166	130	110	60	71	61	86	194	93	111	138
Expenses	111	139	110	87	63	73	65	67	93	76	95	121
Operating Profit	8	28	20	23	-4	-2	-4	20	101	17	16	18
OPM %	7%	17%	16%	21%	-6%	-3%	-6%	23%	52%	18%	14%	13%
Other Income	25	4	8	-2	4	1	-30	0	-4	-4	1	2
Interest	27	24	15	19	10	7	20	26	20	12	5	2
Depreciation	9	11	9	10	11	7	8	8	17	14	13	7
Profit before tax	-3	-3	4	-8	-20	-15	-62	-14	59	-13	-1	11
Tax %	45%	31%	-5%	-19%	-5%	-59%	1%	-29%	35%	-0%	182%	29%
Net Profit	-5	-5	4	-7	-19	-6	-63	-10	38	-13	-3	8
EPS in Rs	-3.05	-2.29	1.67	-2.51	-6.14	-1.97	-21.10	-4.03	13.59	-4.30	-0.75	2.22
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-171.43%	68.42%	-950.00%	84.13%	480.00%	-134.21%	76.92%	366.67%
Change in YoY Net Profit Growth (%)	0.00%	239.85%	-1018.42%	1034.13%	395.87%	-614.21%	211.13%	289.74%

Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	2%
5 Years:	18%
3 Years:	-11%
TTM:	25%

Compounded Profit Growth
10 Years:	9%
5 Years:	18%
3 Years:	-43%
TTM:	375%

Stock Price CAGR
10 Years:	6%
5 Years:	39%
3 Years:	-1%
1 Year:	7%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	0%
Last Year:	9%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:46 am

Month	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	22	22	22	22	28	28	29	29	29	31	33	36
Reserves	30	20	22	16	21	15	-43	-54	-15	15	35	68
Borrowings	164	137	121	126	113	96	141	163	130	75	59	39
Other Liabilities	113	100	77	88	67	76	73	52	42	31	30	33
Total Liabilities	329	279	242	252	229	216	200	190	186	152	157	176
Fixed Assets	162	122	104	133	116	108	105	98	94	68	58	86
CWIP	22	27	30	24	28	31	28	26	18	16	23	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	145	130	107	94	85	77	68	66	74	67	76	90
Total Assets	329	279	242	252	229	216	200	190	186	152	157	176

Below is a detailed analysis of the balance sheet data for Lyka Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2024) to 36.00 Cr., marking an increase of 3.00 Cr..
For Reserves, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 33.00 Cr..
For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 59.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 20.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 33.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 3.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 176.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 28.00 Cr..
For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 23.00 Cr..
For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Mar 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 76.00 Cr. (Mar 2024) to 90.00 Cr., marking an increase of 14.00 Cr..
For Total Assets, as of Mar 2025, the value is 176.00 Cr.. The value appears strong and on an upward trend. It has increased from 157.00 Cr. (Mar 2024) to 176.00 Cr., marking an increase of 19.00 Cr..

Notably, the Reserves (68.00 Cr.) exceed the Borrowings (39.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	89	27	12	31	11	27	5	9	79	9	2	2
Cash from Investing Activity +	-57	37	17	-13	-3	-4	-0	-0	-6	7	-9	-12
Cash from Financing Activity +	-26	-60	-30	-19	-10	-23	3	-12	-63	-22	2	5
Net Cash Flow	6	4	-1	-0	-3	-1	9	-3	10	-5	-6	-5

Free Cash Flow

Month	Jun 2014n n 15m	Jun 2015	Mar 2016n n 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	8.00	-109.00	20.00	-103.00	-117.00	-98.00	-145.00	-143.00	-29.00	-58.00	-43.00	-21.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	211	209	124	121	97	125	75	48	37	35	79	89
Inventory Days	99	91	77	56	90	139	65	69	41	56	68	78
Days Payable	236	363	220	218	266	301	216	192	141	96	91	98
Cash Conversion Cycle	73	-64	-18	-41	-79	-37	-75	-76	-63	-5	55	68
Working Capital Days	96	-106	-88	-75	-191	-456	-181	-156	-71	6	34	71
ROCE %	10%	2%	10%	7%	9%	-8%	-5%	-6%	10%	61%	5%	4%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	20.00%	20.04%	47.79%	47.80%	47.58%	47.58%	51.00%	54.58%	54.81%	54.81%	54.81%	58.11%
FIIs	2.07%	1.13%	1.12%	0.76%	0.57%	0.37%	0.18%	0.17%	0.18%	0.17%	0.17%	0.15%
DIIs	1.85%	0.47%	1.19%	3.99%	4.00%	4.00%	3.74%	0.41%	0.41%	0.62%	0.81%	0.75%
Public	76.08%	78.36%	49.89%	47.45%	47.85%	48.05%	45.08%	44.84%	44.61%	44.41%	44.21%	40.99%
No. of Shareholders	20,672	27,720	26,220	26,969	28,433	28,515	26,820	27,202	26,652	26,422	25,717	25,716

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-0.79	-4.63	13.57	-4.07	-21.29
Diluted EPS (Rs.)	-0.79	-4.63	13.57	-4.07	-21.29
Cash EPS (Rs.)	3.08	0.32	19.45	-0.61	-19.03
Book Value[Excl.RevalReserv]/Share (Rs.)	20.63	14.88	4.70	-8.75	-5.27
Book Value[Incl.RevalReserv]/Share (Rs.)	20.63	14.88	4.70	-8.75	-5.27
Revenue From Operations / Share (Rs.)	33.60	30.33	67.65	30.06	21.43
PBDIT / Share (Rs.)	5.19	6.59	35.99	7.41	-0.20
PBIT / Share (Rs.)	1.32	1.99	29.94	4.50	-2.99
PBT / Share (Rs.)	-0.28	-4.29	20.65	-4.93	-21.57
Net Profit / Share (Rs.)	-0.79	-4.29	13.40	-3.52	-21.83
NP After MI And SOA / Share (Rs.)	-0.75	-4.30	13.59	-4.03	-21.10
PBDIT Margin (%)	15.44	21.74	53.19	24.63	-0.94
PBIT Margin (%)	3.92	6.54	44.25	14.98	-13.96
PBT Margin (%)	-0.83	-14.15	30.52	-16.39	-100.63
Net Profit Margin (%)	-2.35	-14.13	19.80	-11.69	-101.84
NP After MI And SOA Margin (%)	-2.23	-14.19	20.09	-13.39	-98.45
Return on Networth / Equity (%)	-3.65	-29.07	292.38	0.00	0.00
Return on Capital Employeed (%)	3.66	5.12	99.57	9.17	-6.41
Return On Assets (%)	-1.58	-8.71	21.01	-6.08	-30.24
Long Term Debt / Equity (X)	0.62	1.38	4.63	-5.84	-8.75
Total Debt / Equity (X)	0.84	1.55	9.66	-6.24	-9.75
Asset Turnover Ratio (%)	0.72	0.44	0.82	0.30	0.18
Current Ratio (X)	1.35	1.36	0.52	0.59	0.54
Quick Ratio (X)	1.09	1.14	0.44	0.50	0.43
Inventory Turnover Ratio (X)	3.89	3.05	4.31	2.23	2.12
Interest Coverage Ratio (X)	3.51	1.71	5.13	0.81	-0.02
Interest Coverage Ratio (Post Tax) (X)	0.54	0.51	3.23	0.65	-0.46
Enterprise Value (Cr.)	402.09	381.55	501.74	229.87	166.02
EV / Net Operating Revenue (X)	3.62	4.10	2.59	2.67	2.70
EV / EBITDA (X)	23.42	18.85	4.86	10.82	-286.39
MarketCap / Net Operating Revenue (X)	3.15	3.45	2.00	0.86	0.59
Price / BV (X)	5.14	7.07	29.17	-2.89	-2.55
Price / Net Operating Revenue (X)	3.15	3.45	2.00	0.86	0.59
EarningsYield	-0.01	-0.04	0.10	-0.15	-1.65

After reviewing the key financial ratios for Lyka Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 5. It has increased from -4.63 (Mar 23) to -0.79, marking an increase of 3.84.
For Diluted EPS (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 5. It has increased from -4.63 (Mar 23) to -0.79, marking an increase of 3.84.
For Cash EPS (Rs.), as of Mar 24, the value is 3.08. This value is within the healthy range. It has increased from 0.32 (Mar 23) to 3.08, marking an increase of 2.76.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 20.63. It has increased from 14.88 (Mar 23) to 20.63, marking an increase of 5.75.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 20.63. It has increased from 14.88 (Mar 23) to 20.63, marking an increase of 5.75.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 33.60. It has increased from 30.33 (Mar 23) to 33.60, marking an increase of 3.27.
For PBDIT / Share (Rs.), as of Mar 24, the value is 5.19. This value is within the healthy range. It has decreased from 6.59 (Mar 23) to 5.19, marking a decrease of 1.40.
For PBIT / Share (Rs.), as of Mar 24, the value is 1.32. This value is within the healthy range. It has decreased from 1.99 (Mar 23) to 1.32, marking a decrease of 0.67.
For PBT / Share (Rs.), as of Mar 24, the value is -0.28. This value is below the healthy minimum of 0. It has increased from -4.29 (Mar 23) to -0.28, marking an increase of 4.01.
For Net Profit / Share (Rs.), as of Mar 24, the value is -0.79. This value is below the healthy minimum of 2. It has increased from -4.29 (Mar 23) to -0.79, marking an increase of 3.50.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -0.75. This value is below the healthy minimum of 2. It has increased from -4.30 (Mar 23) to -0.75, marking an increase of 3.55.
For PBDIT Margin (%), as of Mar 24, the value is 15.44. This value is within the healthy range. It has decreased from 21.74 (Mar 23) to 15.44, marking a decrease of 6.30.
For PBIT Margin (%), as of Mar 24, the value is 3.92. This value is below the healthy minimum of 10. It has decreased from 6.54 (Mar 23) to 3.92, marking a decrease of 2.62.
For PBT Margin (%), as of Mar 24, the value is -0.83. This value is below the healthy minimum of 10. It has increased from -14.15 (Mar 23) to -0.83, marking an increase of 13.32.
For Net Profit Margin (%), as of Mar 24, the value is -2.35. This value is below the healthy minimum of 5. It has increased from -14.13 (Mar 23) to -2.35, marking an increase of 11.78.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.23. This value is below the healthy minimum of 8. It has increased from -14.19 (Mar 23) to -2.23, marking an increase of 11.96.
For Return on Networth / Equity (%), as of Mar 24, the value is -3.65. This value is below the healthy minimum of 15. It has increased from -29.07 (Mar 23) to -3.65, marking an increase of 25.42.
For Return on Capital Employeed (%), as of Mar 24, the value is 3.66. This value is below the healthy minimum of 10. It has decreased from 5.12 (Mar 23) to 3.66, marking a decrease of 1.46.
For Return On Assets (%), as of Mar 24, the value is -1.58. This value is below the healthy minimum of 5. It has increased from -8.71 (Mar 23) to -1.58, marking an increase of 7.13.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.62. This value is within the healthy range. It has decreased from 1.38 (Mar 23) to 0.62, marking a decrease of 0.76.
For Total Debt / Equity (X), as of Mar 24, the value is 0.84. This value is within the healthy range. It has decreased from 1.55 (Mar 23) to 0.84, marking a decrease of 0.71.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.72. It has increased from 0.44 (Mar 23) to 0.72, marking an increase of 0.28.
For Current Ratio (X), as of Mar 24, the value is 1.35. This value is below the healthy minimum of 1.5. It has decreased from 1.36 (Mar 23) to 1.35, marking a decrease of 0.01.
For Quick Ratio (X), as of Mar 24, the value is 1.09. This value is within the healthy range. It has decreased from 1.14 (Mar 23) to 1.09, marking a decrease of 0.05.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.89. This value is below the healthy minimum of 4. It has increased from 3.05 (Mar 23) to 3.89, marking an increase of 0.84.
For Interest Coverage Ratio (X), as of Mar 24, the value is 3.51. This value is within the healthy range. It has increased from 1.71 (Mar 23) to 3.51, marking an increase of 1.80.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.54. This value is below the healthy minimum of 3. It has increased from 0.51 (Mar 23) to 0.54, marking an increase of 0.03.
For Enterprise Value (Cr.), as of Mar 24, the value is 402.09. It has increased from 381.55 (Mar 23) to 402.09, marking an increase of 20.54.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.62. This value exceeds the healthy maximum of 3. It has decreased from 4.10 (Mar 23) to 3.62, marking a decrease of 0.48.
For EV / EBITDA (X), as of Mar 24, the value is 23.42. This value exceeds the healthy maximum of 15. It has increased from 18.85 (Mar 23) to 23.42, marking an increase of 4.57.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has decreased from 3.45 (Mar 23) to 3.15, marking a decrease of 0.30.
For Price / BV (X), as of Mar 24, the value is 5.14. This value exceeds the healthy maximum of 3. It has decreased from 7.07 (Mar 23) to 5.14, marking a decrease of 1.93.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.15. This value exceeds the healthy maximum of 3. It has decreased from 3.45 (Mar 23) to 3.15, marking a decrease of 0.30.
For EarningsYield, as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 23) to -0.01, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lyka Labs Ltd as of June 26, 2025 is: 113.04

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 26, 2025, Lyka Labs Ltd is Overvalued by 1.70% compared to the current share price 115.00

Intrinsic Value of Lyka Labs Ltd as of June 26, 2025 is: 168.00

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 26, 2025, Lyka Labs Ltd is Undervalued by 46.09% compared to the current share price 115.00

Last 5 Year EPS CAGR: 48.62%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of -93.08, which is a positive sign. The stock has a low average Cash Conversion Cycle of -21.83, which is a positive sign.	The stock has a low average ROCE of 8.25%, which may not be favorable. The company has higher borrowings (113.67) compared to reserves (10.83), which may suggest financial risk. The company has not shown consistent growth in sales (111.58) and profit (-5.42).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
1. Net Profit Margin: -2.35%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 3.66% (Industry Average ROCE: 16.65%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -3.65% (Industry Average ROE: 15.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.54
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.09
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 51.7 (Industry average Stock P/E: 103.22)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.84
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 134.70 Cr. and Equity Capital is Rs. 35.69 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	4801/B & 4802/A, G.I.D.C. Industrial Estate, Ankleshwar Gujarat 393002	companysecretary@lykalabs.com. http://www.lykalabs.com

Management
Name	Position Held
Mr. Babulal Jain	Chairman
Mr. Kunal Gandhi	Managing Director & CEO
Mr. Yogesh B Shah	Executive Director & CFO
Mr. Shashil Mendosa	Non Executive Director
Mr. Prashant Godha	Non Executive Director
Mrs. Dhara Shah	Independent Director
Mr. Neeraj Golas	Independent Director

FAQ

What is the intrinsic value of Lyka Labs Ltd?

Lyka Labs Ltd's intrinsic value (as of 26 June 2025) is 113.04 — 1.70% lower the current market price of 115.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 410 Cr. market cap, FY2025-2026 high/low of 177/90.2, reserves of 68 Cr, and liabilities of 176 Cr.

What is the Market Cap of Lyka Labs Ltd?

The Market Cap of Lyka Labs Ltd is 410 Cr..

What is the current Stock Price of Lyka Labs Ltd as on 26 June 2025?

The current stock price of Lyka Labs Ltd as on 26 June 2025 is 115.

What is the High / Low of Lyka Labs Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Lyka Labs Ltd stocks is ₹177/90.2.

What is the Stock P/E of Lyka Labs Ltd?

The Stock P/E of Lyka Labs Ltd is 51.7.

What is the Book Value of Lyka Labs Ltd?

The Book Value of Lyka Labs Ltd is 29.0.

What is the Dividend Yield of Lyka Labs Ltd?

The Dividend Yield of Lyka Labs Ltd is 0.00 %.

What is the ROCE of Lyka Labs Ltd?

The ROCE of Lyka Labs Ltd is 9.93 %.

What is the ROE of Lyka Labs Ltd?

The ROE of Lyka Labs Ltd is 9.24 %.

What is the Face Value of Lyka Labs Ltd?

The Face Value of Lyka Labs Ltd is 10.0.